AbCellera Biologics (NASDAQ:ABCL) reported quarterly earnings results on February 24, 2026 that exceeded analyst expectations.
The Healthcare company reported earnings per share of $-0.03, beating the consensus estimate of $-0.18 by $0.15 per share. Revenue came in at $44.9M, beating the estimate of $6.7M.
AbCellera Biologics's stock moved following the earnings release. The stock currently trades at $3.35 with a market capitalization of $1.1B.